AKR.L Regulatory News (AKR)

20 Dec 2007 07:01

Akers Biosciences, Inc.20 December 2007 20 December 2007 Akers Biosciences, Inc. ("ABI" or the "Company") Directors Shareholding & Additional Listing Akers Biosciences, Inc. which develops, manufactures, and supplies rapid, pointof care screening and testing products announces that several of its directorshave purchased shares of the Company's common stock and a retiring executive hasbeen issued warrants to purchase shares of the Company's common stock. David Wilbraham, Chairman, has converted £9,000 of director's fees into 61,017shares of common stock. Mr. Wilbraham's shareholdings currently total 929,017common shares. Edward Mulhare, non-executive director, has converted $11,250 of director's feesinto 37,790 shares of common stock. Mr. Mulhare's shareholdings currently total900,940 shares. Daniel Seckinger, M.D non-executive director has converted $57,375 of directorand consulting fees into 192,728 shares of common stock. Dr. Seckinger'sshareholdings currently total 967,616 common shares. Carl E. King, retiring president of the Company's Breath Alcohol DetectionDivision, has converted $114,304 in commission due on sales into warrants topurchase 383,957 shares of common stock. The exercise price of such warrantswill be $.001 and shall vest immediately. The exchange rate used in the transactions is £1.00 = $2.0182 Application has been made to the London Stock Exchange for 291,535 New OrdinaryShares ("Shares"), which will rank pari passu with existing Ordinary Shares, tobe admitted to trading, such admission expected to take place on 4 January 2008. The number of Shares with voting rights in issue following this transaction is66,384,104. Therefore the total number of voting rights in the Company is66,384,104 which number may be used by shareholders as the denominator for thecalculations by which they will determine if they are required to notify theirinterest in, or a change in their interest in, the Company under the FSA'sDisclosure and Transparency Rules. Enquiries: Thomas A. Nicolette, PresidentAkers Biosciences, Inc.Tel. 001 856 848 8698 Alasdair YounieArbuthnot SecuritiesTel. 020 7012 2000 This information is provided by RNS The company news service from the London Stock Exchange